These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 34506342)

  • 1. Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
    Orkin C; Ajana F; Kityo C; Koenig E; Natukunda E; Gandhi-Patel B; Wang H; Liu Y; Wei X; White K; Makadzange T; Pikora C; McNicholl I; Collins SE; Brainard D; Chuck SK
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):393-398. PubMed ID: 34506342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
    Hagins D; Kumar P; Saag M; Wurapa AK; Brar I; Berger D; Osiyemi O; Hileman CO; Ramgopal MN; McDonald C; Blair C; Andreatta K; Collins SE; Brainard DM; Martin H;
    J Acquir Immune Defic Syndr; 2021 Sep; 88(1):86-95. PubMed ID: 34397746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
    Orkin C; Antinori A; Rockstroh JK; Moreno-Guillén S; Martorell CT; Molina JM; Lazzarin A; Maggiolo F; Yazdanpanah Y; Andreatta K; Huang H; Hindman JT; Martin H; Pozniak A
    AIDS; 2024 Jun; 38(7):983-991. PubMed ID: 38349226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
    d'Arminio Monforte A; Tavelli A; Di Biagio A; Sarmati L; Marchetti GC; Bai F; Cingolani A; Quiros Roldan E; Mussini C; Lichtner M; Vergori A; Piconi S; Orofino G; Fusco FM; Bandera A; Nozza S; Castagna A; Antinori A;
    J Antimicrob Chemother; 2024 Jun; 79(6):1279-1288. PubMed ID: 38581349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
    Mills AM; Rizzardini G; Ramgopal MN; Osiyemi OO; Bogner JR; Hagins DP; Paredes R; Reynes J; Rockstroh JK; Carr A; Su FH; Klopfer SO; Eves K; Plank RM; Correll T; Fox MC
    Lancet HIV; 2024 Jun; 11(6):e357-e368. PubMed ID: 38734016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
    Kityo C; Hagins D; Koenig E; Avihingsanon A; Chetchotisakd P; Supparatpinyo K; Gankina N; Pokrovsky V; Voronin E; Stephens JL; DeJesus E; Wang H; Acosta RK; Cao H; Quirk E; Martin H; Makadzange T
    J Acquir Immune Defic Syndr; 2019 Nov; 82(3):321-328. PubMed ID: 31609930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials.
    Avihingsanon A; Chetchotisakd P; Kiertiburanakul S; Ratanasuwan W; Siripassorn K; Supparatpinyo K; Martin H; Wang H; Wong T; Wang HY
    HIV Med; 2023 Mar; 24(3):290-300. PubMed ID: 36912172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
    Sax PE; Rockstroh JK; Luetkemeyer AF; Yazdanpanah Y; Ward D; Trottier B; Rieger A; Liu H; Acosta R; Collins SE; Brainard DM; Martin H;
    Clin Infect Dis; 2021 Jul; 73(2):e485-e493. PubMed ID: 32668455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
    Sax PE; Andreatta K; Molina JM; Daar ES; Hagins D; Acosta R; D'Antoni ML; Chang S; Martin R; Liu H; Blair C; McNicholl I; Gallant J; Collins SE; Martin H; White KL
    AIDS; 2022 Sep; 36(11):1511-1520. PubMed ID: 35466963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
    Hoffmann C; Schewe K; Fenske S; Buhk T; Sabranski M; Adam A; Hansen S; Stellbrink HJ
    Antivir Ther; 2020; 25(2):83-90. PubMed ID: 32235038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
    Rodriguez CA; Natukunda E; Strehlau R; Venter EL; Rungmaitree S; Cunningham CK; Lalloo U; Kosalaraksa P; HellstrÖm E; Liberty A; McGrath EJ; Kaur M; Leisegang R; Hindman JT; Vieira VA; Kersey K; Cotton MF; Rakhmanina N; Gaur AH
    Lancet HIV; 2024 May; 11(5):e300-e308. PubMed ID: 38621393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
    Hidalgo-Tenorio C; Sequera S; Vivancos MJ; Vinuesa D; Collado A; Santos IL; Sorni P; Cabello-Clotet N; Montero M; Font CR; Terron A; Galindo MJ; Martinez O; Ryan P; Omar-Mohamed M; Albendín-Iglesias H; Javier R; Ruz MÁL; Romero A; Garcia-Vallecillos C
    Int J Antimicrob Agents; 2024 Jun; 63(6):107164. PubMed ID: 38574873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
    Armenia D; Forbici F; Bertoli A; Berno G; Malagnino V; Gagliardini R; Borghi V; Gennari W; Cicalini S; Buonomini A; Teti E; Lanini S; Latini A; Sarmati L; Mussini C; Andreoni M; Antinori A; Perno CF; Ceccherini-Silberstein F; Santoro MM
    J Glob Antimicrob Resist; 2022 Sep; 30():326-334. PubMed ID: 35793776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
    Iwuji CC; Churchill D; Bremner S; Perry N; To Y; Lambert D; Bruce C; Waters L; Orkin C; Geretti AM
    BMC Infect Dis; 2020 Jul; 20(1):524. PubMed ID: 32689975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
    D'Antoni ML; Andreatta K; Acosta R; Martin H; Chang S; Martin R; White KL
    J Acquir Immune Defic Syndr; 2022 Apr; 89(4):433-440. PubMed ID: 34897227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
    Chivite I; Berrocal L; de Lazzari E; Navadeh S; Lluis-Ganella C; Inciarte A; de la Mora L; González-Cordón A; Martínez-Rebollar M; Laguno M; Torres B; Blanco JL; Martínez E; Mallolas J; Ambrosioni J
    J Antimicrob Chemother; 2024 Aug; 79(8):1775-1783. PubMed ID: 38758191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study.
    Wong A; Brunetta J; De Wet J; Logue K; Loemba H; Saifi T; Mumm D; Marongiu A; Harrison R; Thorpe D; Trottier B
    Medicine (Baltimore); 2024 Apr; 103(16):e37785. PubMed ID: 38640301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.